Rating Rationale
January 05, 2021 | Mumbai
Amoli Organics Private Limited
Ratings upgraded to 'CRISIL A- / CRISIL A2+ '; outlook revised to 'Stable'; rated amount enhanced for Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.265.82 Crore (Enhanced from Rs.234.82 Crore)
Long Term RatingCRISIL A-/Stable (Upgraded from 'CRISIL BBB+ / Positive' and outlook revised to 'Stable')
Short Term RatingCRISIL A2+ (Upgraded from 'CRISIL A2 ')
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL has upgraded its ratings on the bank facilities of Amoli Organics Private Limited (AOPL) to 'CRISIL A-/Stable/CRISIL A2+' from 'CRISIL BBB+/Positive/CRISIL A2'.

 

The upgrade reflects sustenance of improved AOPL’s business risk profile marked by healthy growth in revenue as well as operating margin which is expected to sustain over the medium term. Higher offtake from customers for existing products as well as steady demand for the new commercialized products has led to an improvement in revenue. AOPL’s revenue grew at compounded annual growth rate of 8.17% over last three years through fiscal 2020. Further lockdown and other measures taken by the central and state governments to contain the spread of COVID-19 is expected to have minimal impact in fiscal 2021 as seen from the healthy YTD sales of Rs 366 crore as on November 2020. The operating profitability continues to remain healthy at around 18 percent for fiscal 2020 which is expected to improve. Increase in customer base and monetization of existing products in newer geographies is expected to further drive revenue growth over the medium term while sustain operating profits backed by increasing capacity. The company’s financial risk profile is also healthy and has improved over past 3 years which is expected to sustain.

 

The ratings continue to reflect promoters' extensive industry experience and their established customer relationships and the company’s healthy financial risk profile. These strengths are partially offset by its working capital-intensive operations, and susceptibility of operating performance to product concentration risk, raw material price fluctuations and regulatory risks.

Key Rating Drivers & Detailed Description

Strengths:

  • Promoters' extensive industry experience and established customer relationships: AOPL has been active in the API manufacturing segment since 1991, and its promoters have over 3 decades of relevant industry experience. Over the years company has built customer base across geographies resulting in diversification in revenue profile. Company caters to over 50 countries while generating steady sales from exports to tune of 48-50%. On the back of constant upgrades in production facilities and R&D, the company has obtained approvals from various regulatory authorities which has further strengthened the healthy relations with customers. Customers include major global players such as Aurobindo Pharma Ltd, Gsk Consumer Healthcare Sa, Olon SPA, Torrent Pharmaceuticals Limited among others.

 

  • Healthy financial risk profile: Total outside liabilities to adjusted networth (TOLANW) of 1.54 times on a healthy networth base of Rs 176 crore reflects moderate capital structure. TOLANW has been improving over past 3 years in spite of capex and working capital intensive operations and is expected to remain sub 1.5 times over the medium term.  On back of moderate operating profits, debt protection metrics is comfortable as indicated by interest coverage ratio and NCATD at 5.99 times and 0.53 times for fiscal 2020.

 

Weakness:

  • Working capital intensive operations: AOPL’s operations are working capital intensive as reflected in gross current assets (GCAs) in the range of 202-215 days for last 3 years ending March 2020 primarily driven by receivables of around 111-123 days. Incremental working capital requirements arising from sharp growth, spontaneous operational requirements on account of inventory or capex to remain key rating factor.

 

  • Susceptibility of operating performance to product concentration risk, raw material price fluctuations and regulatory risk: Revenue could be impacted as, company derives around 30-35% of revenue from the single product, while operating profitability will remain susceptible to any sharp changes in raw material prices or competition from peers over the medium term. Further, being in pharmaceutical industry, the operations of the company remains susceptible to regulatory changes both in domestic and export market.

Liquidity: Adequate

AOPL has adequate liquidity driven by expected cash accruals of more than Rs. 80 crore per annum in fiscal 2021 and 2022 and cash and cash equivalents (including encumbered and unencumbered) of Rs.6.89 crore as on March 31, 2020. The company’s fund based limits have remained utilized to the tune of 80% on an average over the 6 months ended September 2020. The company has long term repayment obligation of Rs 10 crore and Rs 23 crore in fiscal 2021 and fiscal 2022 respectively. Capex is expected to be around Rs. 30-40 crore each over fiscal 2021 and 2022 partly funded by debt. CRISIL believes the company has sufficient accruals and cash and cash equivalents to part finance its capex requirements and incremental working capital needs.

 Outlook:  Stable

CRISIL believes AOPL will continue to benefit from extensive experience of promoters and established relationships with reputed pharmaceutical companies over the medium term.

Rating Sensitivity factors

Upward factor

  • Healthy cash accruals driven by significant improvement in revenue and sustained improvement in operating margin above 20%
  • Diversification of product profile
  • Sustaining the financial risk profile, driven by improvement in working capital cycle

 

Downward factor

  • Any debt-funded capital expenditure or a stretch in the working capital cycle, leading to weakening of the financial risk profile with TOLANW increasing above 2 times
  • Decline in revenue and profitability, resulting in a reduction in cash accrual

About the Company

 

AOPL was incorporated by Mr Manish Doshi and Mr Umed Doshi in 1991. It manufactures bulk drugs/active pharmaceutical ingredients, and caters primarily to the anti-inflammatory, anti-fungal, and anti-depressant segments. Its manufacturing facilities are at Vapi and Vadodara in Gujarat.

Key Financial Indicators

Particulars

Unit

2020

2019

Revenue

Rs crore

514.03

465.47

Profit After Tax (PAT)

Rs crore

39.14

32.41

PAT Margin

%

7.6

7

Adjusted debt/adjusted networth

Times

0.69

0.86

Interest coverage

Times

5.93

6.87

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of Instrument

Date of Allotment

Coupon Rate (%)

Maturity Date

Issue Size (Rs.Cr)

Complexity

levels

Rating Assigned with Outlook

NA

Bank Guarantee

NA

NA

NA

2.5

NA

CRISIL A2+

NA

Cash Credit

NA

NA

NA

119

NA

CRISIL A-/Stable

NA

External Commercial Borrowings

NA

NA

Jun-2024

19.56

NA

CRISIL A-/Stable

NA

FCNR (B) Long Term Loan

NA

NA

Mar-2025

29.38

NA

CRISIL A-/Stable

NA

Letter of Credit

NA

NA

NA

30

NA

CRISIL A2+

NA

Line of Credit

NA

NA

NA

5.3

NA

CRISIL A-/Stable

NA

Proposed Letter of Credit

NA

NA

NA

11

NA

CRISIL A2+

NA

Proposed Long Term Bank Loan Facility

NA

NA

NA

20.42

NA

CRISIL A-/Stable

NA

Rupee Term Loan

NA

NA

Jun-2025

23.66

NA

CRISIL A-/Stable

NA

Standby Line of Credit

NA

NA

NA

5

NA

CRISIL A-/Stable

 

Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 222.32 CRISIL A-/Stable   -- 25-06-20 CRISIL BBB+/Positive 13-12-19 CRISIL BBB+/Positive 23-08-18 CRISIL BBB+/Stable / CRISIL A2 CRISIL A3+ / CRISIL BBB/Stable
      --   --   -- 06-12-19 CRISIL BBB+/Positive / CRISIL A2 16-08-18 CRISIL BBB+/Stable / CRISIL A2 --
      --   --   -- 30-03-19 CRISIL BBB+/Stable / CRISIL A2   -- --
      --   --   -- 07-03-19 CRISIL BBB+/Stable / CRISIL A2   -- --
Non-Fund Based Facilities ST 43.5 CRISIL A2+   -- 25-06-20 CRISIL A2 13-12-19 CRISIL A2 23-08-18 CRISIL A2 CRISIL A3+
      --   --   -- 06-12-19 CRISIL A2 16-08-18 CRISIL A2 --
      --   --   -- 30-03-19 CRISIL A2   -- --
      --   --   -- 07-03-19 CRISIL A2   -- --
All amounts are in Rs.Cr.
 
 
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 2.5 CRISIL A2+ Bank Guarantee 2.5 CRISIL A2
Cash Credit 119 CRISIL A-/Stable Cash Credit 92 CRISIL BBB+/Positive
External Commercial Borrowings 19.56 CRISIL A-/Stable External Commercial Borrowings 20 CRISIL BBB+/Positive
FCNR (B) Long Term Loan 29.38 CRISIL A-/Stable FCNR (B) Long Term Loan 30.43 CRISIL BBB+/Positive
Letter of Credit 30 CRISIL A2+ Letter of Credit 32 CRISIL A2
Line of Credit 5.3 CRISIL A-/Stable Proposed Cash Credit Limit 25 CRISIL BBB+/Positive
Proposed Letter of Credit 11 CRISIL A2+ Proposed Letter of Credit 10 CRISIL A2
Proposed Long Term Bank Loan Facility 20.42 CRISIL A-/Stable Proposed Long Term Bank Loan Facility 13.45 CRISIL BBB+/Positive
Rupee Term Loan 23.66 CRISIL A-/Stable Rupee Term Loan 4.44 CRISIL BBB+/Positive
Standby Line of Credit 5 CRISIL A-/Stable Standby Line of Credit 5 CRISIL BBB+/Positive
Total 265.82 - Total 234.82 -
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
The Rating Process
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Rahul Subrato Kumar Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Rushabh Pramod Borkar
Manager - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8302
Rushabh.Borkar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 95,000 MSMEs have been rated by us.



CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit www.crisil.com/privacy. You can view the Company’s Customer Privacy at https://www.spglobal.com/privacy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL

CRISIL uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL's use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html